Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warren P Mason

Showing results (111-120 of 116) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 116 results.
The Lancet. Oncology|October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Nature Medicine|May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Neuro-Oncology|April 29, 2021
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC Mircea S Tesileanu, Martin J van den Bent, Marc Sanson, et al.
Acta Neuropathologica|March 19, 2021
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutationsC Mircea S Tesileanu, Wies R Vallentgoed, Marc Sanson, et al.
Pageof 12

Showing results (111-120 of 116) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 116 results.
The Lancet. Oncology|October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Nature Medicine|May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
The Lancet. Oncology|May 17, 2021
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 studyMartin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, et al.
The Lancet. Oncology|December 25, 2025
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trialMartin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, et al.
Neuro-Oncology|April 29, 2021
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC Mircea S Tesileanu, Martin J van den Bent, Marc Sanson, et al.
Acta Neuropathologica|March 19, 2021
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutationsC Mircea S Tesileanu, Wies R Vallentgoed, Marc Sanson, et al.
Pageof 12